(firstQuint)Phase I/II Trial of Antagonism of HER in GI Cancer.

 PANTHER is a registered phase I/phase II trial in patients with recurrent or metastatic colorectal cancer.

 The phase II part of the study will be a single arm trial.

 Patients will receive AZD8931 (an EGFR/ERBB inhibitor) in combination with FOLinic acid, Fluorouracil and IRInotecan (FOLFIRI), Treatment will be given in two-weekly cycles.

 Phase II's primary objective is to evaluate the Best overall response.

 Phase I/II Trial of Antagonism of HER in GI Cancer@highlight

Recruitment to phase I of the PANTHER trial is complete.

 Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.

